aTyr Pharma, Inc.

aTyr Pharma announced a corporate restructuring that includes a 60% workforce reduction to advance its lead therapeutic candidate efzofitimod in interstitial lung disease. The company's second-quarter 2026 net loss narrowed to $10.31 million, or $0.11 per share, from $19.53 million, or $0.22 per share, a year earlier. Cash and equivalents stood at $58.9 million as of June 30, 2026, which aTyr expects will fund operations into late 2028. The restructuring and additional cost-saving measures are projected to reduce annualized operating expenses by approximately $13 million starting in the fourth quarter of 2026. Chief Financial Officer Jill Broadfoot will step down on September 30, 2026, and Vice President of Finance Brandon Yaras will become CFO on October 1, 2026. The company anticipates FDA feedback on the Phase 3 protocol for efzofitimod in pulmonary sarcoidosis by the end of August 2026, and topline results from the Phase 2 EFZO-CONNECT study in systemic sclerosis-related ILD are expected in the first quarter of 2027.